Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SCYNEXIS, Inc. (SCYX)
USD4.84
-0.09 (-1.83%)
US NASDAQ Healthcare Medical - Pharmaceuticals
Address
1 Evertrust Plaza 07302-6548
Jersey City, NJ, US
Jersey City, NJ, US
CEO
David Angulo
Website
scynexis.com
IPO
2014-05-02
CIK 1178253 ISIN US8112923094
Description
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.84
-0.09 (-1.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
65.2K
Beta
1.06
Float Shares
48.61M
Free Float %
96.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.67% | -13.27% | -37.59% | -14.82% | -3.22% | +5.60% | -16.46% | -76.23% | -91.93% | -97.82% | -99.26% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
4.84
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-6.66
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+450.0% ★ Q1'26: -100.0% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+61.4% ★ Q1'26: -281.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-12.3%
-
EBIT margin Medical - Pharmaceuticals: +6.8%-41.0%
-
ROIC Medical - Pharmaceuticals: +6.1%-27.9% Q1'26: +426.3% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+2.9% Q1'26: +3.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.26× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
257.0K
est: 2.91M (-91.2%)
|
257.0K
est: 279.4K (-8.0%)
|
257.0K
est: 279.0K (-7.9%)
|
257.0K
est: 283.2K (-9.3%)
|
121.0K
est: 134.0K (-9.7%)
|
13.16M
est: 11.80M (+11.6%)
|
5.09M
est: 4.71M (+8.1%)
|
140.14M
est: 9.67M (+1,349.8%)
|
3.75M
est: 12.96M (-71.1%)
|
20.60M
est: 9.94M (+107.2%)
|
1.15M
1.15M – 1.15M
-88.4% YoY
|
6.68M
6.68M – 6.68M
+478.6% YoY
|
14.08M
14.08M – 14.08M
+110.9% YoY
|
13.45M
13.45M – 13.45M
-4.4% YoY
|
27.60M
27.60M – 27.60M
+105.2% YoY
|
| EBITDA |
-27.90M
est: -869.0K (-3,110.8%)
|
-29.51M
est: -83.5K (-35,242.9%)
|
-23.16M
est: -83.4K (-27,683.2%)
|
-17.10M
est: -84.6K (-20,102.3%)
|
-51.27M
est: -40.0K (-127,932.4%)
|
-32.92M
est: -3.53M (-833.6%)
|
-59.91M
est: -1.41M (-4,156.4%)
|
70.89M
est: -5.61M (+1,362.9%)
|
-18.58M
est: -7.53M (-146.9%)
|
-8.44M
est: -5.77M (-46.1%)
|
-670.2K
-670.2K – -670.2K
+88.4% YoY
|
-3.88M
-3.88M – -3.88M
-478.6% YoY
|
-8.18M
-8.18M – -8.18M
-110.9% YoY
|
-7.81M
-7.81M – -7.81M
+4.4% YoY
|
-16.03M
-16.03M – -16.03M
-105.2% YoY
|
| EBIT |
-28.35M
est: -871.4K (-3,153.2%)
|
-29.54M
est: -83.7K (-35,176.4%)
|
-23.21M
est: -83.6K (-27,655.5%)
|
-17.15M
est: -84.9K (-20,109.0%)
|
-51.55M
est: -40.2K (-128,288.2%)
|
-33.29M
est: -3.54M (-841.8%)
|
-60.72M
est: -1.41M (-4,202.3%)
|
70.31M
est: -5.62M (+1,350.8%)
|
-20.31M
est: -7.54M (-169.5%)
|
-8.44M
est: -5.78M (-45.9%)
|
-671.1K
-671.1K – -671.1K
+88.4% YoY
|
-3.88M
-3.88M – -3.88M
-478.6% YoY
|
-8.19M
-8.19M – -8.19M
-110.9% YoY
|
-7.82M
-7.82M – -7.82M
+4.4% YoY
|
-16.05M
-16.05M – -16.05M
-105.2% YoY
|
| Net Income |
-32.62M
est: -1.29B (+97.5%)
|
-29.99M
est: -844.82M (+96.5%)
|
-25.06M
est: -445.11M (+94.4%)
|
-12.47M
est: -210.55M (+94.1%)
|
-53.71M
est: -382.44M (+86.0%)
|
-32.87M
est: -48.35M (+32.0%)
|
-62.81M
est: -81.24M (+22.7%)
|
67.04M
est: -36.71M (+282.6%)
|
-21.29M
est: -21.64M (+1.6%)
|
-8.61M
est: -15.65M (+45.0%)
|
-20.31M
-20.31M – -20.31M
-29.8% YoY
|
-12.15M
-12.15M – -12.15M
+40.2% YoY
|
-9.49M
-13.98M – -4.99M
+21.9% YoY
|
-17.14M
-17.14M – -17.14M
-80.7% YoY
|
-18.64M
-18.64M – -18.64M
-8.7% YoY
|
| SGA |
12.17M
est: 12.31M (-1.2%)
|
8.00M
est: 1.18M (+576.1%)
|
8.25M
est: 1.18M (+598.5%)
|
8.68M
est: 1.20M (+624.0%)
|
10.65M
est: 567.3K (+1,776.9%)
|
49.92M
est: 49.95M (-0.1%)
|
62.96M
est: 19.94M (+215.7%)
|
20.92M
est: 40.34M (-48.1%)
|
14.46M
est: 54.08M (-73.3%)
|
14.40M
est: 41.50M (-65.3%)
|
4.82M
4.82M – 4.82M
-88.4% YoY
|
27.87M
27.87M – 27.87M
+478.6% YoY
|
58.76M
58.76M – 58.76M
+110.9% YoY
|
56.15M
56.15M – 56.15M
-4.4% YoY
|
115.19M
115.19M – 115.19M
+105.2% YoY
|
| EPS |
-26.82
est: -26.54 (-1.1%)
|
-15.75
est: -17.41 (+9.6%)
|
-9.37
est: -9.18 (-2.1%)
|
-2.84
est: -4.34 (+34.6%)
|
-9.85
est: -7.88 (-24.9%)
|
-1.25
est: -1.00 (-25.4%)
|
-1.47
est: -1.41 (-4.4%)
|
1.40
est: -0.74 (+290.5%)
|
-0.44
est: -0.43 (-1.5%)
|
-0.17
est: -0.31 (+45.7%)
|
-0.41
-0.41 – -0.41
-29.8% YoY
|
-0.24
-0.24 – -0.24
+40.2% YoY
|
-0.20
-0.28 – -0.10
+19.2% YoY
|
-0.34
-0.34 – -0.34
-74.6% YoY
|
-0.37
-0.37 – -0.37
-8.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-4.12M
OE per share TTM
-0.02
Owner's Yield
-12.09%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
10.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
39
Total invested
12.75M
Insider transactions (90d)
0
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Federated Hermes, Inc. | 5.92M | 19.99% | 5.92M | — | 5.92M | — | HC | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 2 | J. Christopher Donahue | 5.92M | 19.99% | — | 5.92M | — | 5.92M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 3 | Rhodora J. Donahue | 5.92M | 19.99% | — | 5.92M | — | 5.92M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 4 | Thomas R. Donahue | 5.92M | 19.99% | — | 5.92M | — | 5.92M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 5 | Voting Shares Irrevocable Trust | 5.92M | 19.99% | 5.92M | — | 5.92M | — | OO | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 6 | Jon M. Plexico | 2.78M | 11.00% | — | 2.78M | — | 2.78M | HC, IN | California | 2023-06-09 | ↗ |
| 7 | Stonepine Capital Management, LLC | 2.78M | 11.00% | — | 2.78M | — | 2.78M | IA, OO | California | 2023-06-09 | ↗ |
| 8 | Stonepine Capital, L.P. | 2.78M | 11.00% | — | 2.78M | — | 2.78M | PN | California | 2023-06-09 | ↗ |
| 9 | Timothy P. Lynch | 2.78M | 11.00% | — | 2.78M | — | 2.78M | HC, IN | California | 2023-06-09 | ↗ |
| 10 | (. | 2.21M | 9.20% | — | — | 2.21M | — | IN | United States | 2022-02-11 | ↗ |
| 11 | 27-4413262 | 2.21M | 9.20% | 2.21M | — | 2.21M | — | OO | Maryland | 2022-02-11 | ↗ |
| 12 | Bruce S. Kovner | 2.21M | 9.00% | — | 2.21M | — | 2.21M | IN | Delaware | 2022-02-14 | ↗ |
| 13 | CDK Associates, L.L.C. | 2.21M | 9.00% | — | 2.21M | — | 2.21M | OO | Delaware | 2022-02-14 | ↗ |
| 14 | Caxton Corporation | 2.21M | 9.00% | — | 2.21M | — | 2.21M | CO | Delaware | 2022-02-14 | ↗ |
| 15 | Avidity Master Fund LP | 1.98M | 9.90% | — | 1.98M | — | 1.98M | PN, OO | Delaware | 2021-02-16 | ↗ |
| 16 | Avidity Capital Partners (GP) LLC | 1.96M | 9.90% | — | 1.96M | — | 1.96M | OO | Delaware | 2021-02-16 | ↗ |
| 17 | Avidity Capital Partners Fund (GP) LP | 1.96M | 9.90% | — | 1.96M | — | 1.96M | PN, OO | Delaware | 2021-02-16 | ↗ |
| 18 | Avidity Partners Management (GP) LLC | 1.96M | 9.90% | — | 1.96M | — | 1.96M | OO | Delaware | 2021-02-16 | ↗ |
| 19 | Avidity Partners Management LP | 1.96M | 9.90% | — | 1.96M | — | 1.96M | IA, PN | Delaware | 2021-02-16 | ↗ |
| 20 | David Witzke | 1.96M | 9.90% | — | 1.96M | — | 1.96M | IN | Delaware | 2021-02-16 | ↗ |
| 21 | Michael Gregory | 1.96M | 9.90% | — | 1.96M | — | 1.96M | IN | Delaware | 2021-02-16 | ↗ |
| 22 | Kingdon Capital Management, L.L.C. | 1.70M | 5.10% | — | 1.70M | — | 1.70M | IA | Delaware | 2023-04-13 | ↗ |
| 23 | Mark Kingdon | 1.70M | 5.10% | — | 1.70M | — | 1.70M | HC, IN | Delaware | 2023-04-13 | ↗ |
| 24 | Puissance Capital Fund (GP) LLC | 255.7K | 2.34% | — | 255.7K | — | 255.7K | OO | United States America | 2021-02-11 | ↗ |
| 25 | Puissance Capital Management (GP) LLC | 255.7K | 2.34% | — | 255.7K | — | 255.7K | OO | United States America | 2021-02-11 | ↗ |
| 26 | Puissance Capital Management LP | 255.7K | 2.34% | — | 255.7K | — | 255.7K | OO | United States America | 2021-02-11 | ↗ |
| 27 | Puissance Life Science Opportunities Fund VI | 255.7K | 2.34% | — | 255.7K | — | 255.7K | OO | United States America | 2021-02-11 | ↗ |
| 28 | Theodore Wang | 255.7K | 2.34% | — | 255.7K | — | 255.7K | HC, IN | United States America | 2021-02-11 | ↗ |
| 29 | Advisors LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
39
+3 vs prev Q
New positions
11
Closed positions
9
Increased
17
Reduced
10
Put/Call ratio
0.00
Calls held
27.3K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | AVIDITY PARTNERS MANAGEMENT LP | 2.08M -1.3M (-37.9%) | 1.32M -1.3M (-49.0%) | 4.17% -2.563 pp | 0.38% -0.207 pp | USD1.55 -59.4% | 21 qtrs — |
| 2 | GOLDMAN SACHS GROUP INC | 1.98M +2.0M (+100.0%) | 1.26M +1.3M (+100.0%) | 3.98% +3.977 pp | 0.00% +0.000 pp | USD0.63 +0.0% | 1 qtrs NEW |
| 3 | VANGUARD GROUP INC | 1.76M +— (+0.0%) | 1.11M -243.2K (-17.9%) | 3.53% -0.011 pp | 0.00% +0.000 pp | USD4.55 -86.2% | 22 qtrs — |
| 4 | ACADIAN ASSET MANAGEMENT LLC | 583.1K +166.5K (+40.0%) | 367.0K +47.0K (+14.7%) | 1.17% +0.331 pp | 0.00% +0.000 pp | USD1.73 -63.6% | 10 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 449.2K +29.8K (+7.1%) | 284.1K -38.9K (-12.0%) | 0.90% +0.057 pp | 0.00% +0.000 pp | USD3.70 -83.0% | 22 qtrs — |
| 6 | BLACKROCK, INC. | 334.6K +— (+0.0%) | 211.6K -46.0K (-17.9%) | 0.67% -0.002 pp | 0.00% +0.000 pp | USD1.49 -57.7% | 6 qtrs — |
| 7 | YAKIRA CAPITAL MANAGEMENT, INC. | 189.8K +— (+0.0%) | 120.0K -26.1K (-17.9%) | 0.38% -0.001 pp | 0.04% -0.011 pp | USD2.51 -74.9% | 11 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 176.0K +1.4K (+0.8%) | 111.3K -23.1K (-17.2%) | 0.35% +0.002 pp | 0.00% +0.000 pp | USD1.84 -65.8% | 13 qtrs — |
| 9 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 163.9K +— (+0.0%) | 103.7K -22.6K (-17.9%) | 0.33% -0.001 pp | 0.00% -0.001 pp | USD2.21 -71.5% | 22 qtrs — |
| 10 | GSA CAPITAL PARTNERS LLP | 161.0K +56.6K (+54.2%) | 102.0K +22.0K (+27.5%) | 0.32% +0.113 pp | 0.01% +0.002 pp | USD0.69 -8.7% | 3 qtrs — |
| 11 | EMPOWERED FUNDS, LLC | 123.7K +— (+0.0%) | 78.2K -17.0K (-17.9%) | 0.25% -0.001 pp | 0.00% 0.000 pp | USD1.87 -66.3% | 9 qtrs — |
| 12 | STATE STREET CORP | 120.7K +— (+0.0%) | 76.4K -16.6K (-17.9%) | 0.24% -0.001 pp | 0.00% +0.000 pp | USD5.44 -88.4% | 19 qtrs — |
| 13 | CITADEL ADVISORS LLC | 103.9K +103.9K (+100.0%) | 65.7K +65.7K (+100.0%) | 0.21% +0.208 pp | 0.00% +0.000 pp | USD0.63 +0.0% | 1 qtrs NEW |
| 14 | WEALTH EFFECTS LLC | 91.5K -8.0K (-8.0%) | 57.9K -18.8K (-24.5%) | 0.18% -0.017 pp | 0.02% -0.007 pp | USD3.90 -83.8% | 17 qtrs — |
| 15 | NIERENBERG INVESTMENT MANAGEMENT COMPANY, INC. | 75.6K +— (+0.0%) | 47.8K -10.4K (-17.9%) | 0.15% -0.001 pp | 0.02% -0.002 pp | USD1.95 -67.7% | 7 qtrs — |
| 16 | NORTHERN TRUST CORP | 75.5K +30.5K (+67.9%) | 47.7K +13.1K (+37.9%) | 0.15% +0.061 pp | 0.00% +0.000 pp | USD1.87 -66.3% | 22 qtrs — |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 51.0K +51.0K (+100.0%) | 32.3K +32.3K (+100.0%) | 0.10% +0.102 pp | 0.00% +0.000 pp | USD0.63 +0.0% | 4 qtrs — |
| 18 | LPL FINANCIAL LLC | 48.0K -5.7K (-10.6%) | 30.3K -11.0K (-26.6%) | 0.10% -0.012 pp | 0.00% +0.000 pp | USD1.91 -67.0% | 7 qtrs — |
| 19 | MORGAN STANLEY | 46.1K +30.4K (+193.6%) | 29.2K +17.1K (+141.1%) | 0.09% +0.061 pp | 0.00% +0.000 pp | USD1.24 -49.2% | 22 qtrs — |
| 20 | BANK OF NEW YORK MELLON CORP | 35.1K +— (+0.0%) | 22.2K -4.8K (-17.9%) | 0.07% 0.000 pp | 0.00% +0.000 pp | USD5.30 -88.1% | 18 qtrs — |
| 21 | RAYMOND JAMES FINANCIAL INC | 33.4K +11.8K (+54.7%) | 21.1K +4.5K (+27.1%) | 0.07% +0.024 pp | 0.00% +0.000 pp | USD0.84 -25.0% | 4 qtrs — |
| 22 | UBS GROUP AG | 23.5K -28.6K (-54.9%) | 14.9K -25.3K (-63.0%) | 0.05% -0.058 pp | 0.00% +0.000 pp | USD1.34 -53.0% | 22 qtrs — |
| 23 | PDS PLANNING, INC | 15.0K +— (+0.0%) | 9.5K -2.1K (-17.9%) | 0.03% 0.000 pp | 0.00% 0.000 pp | USD0.77 -18.2% | 8 qtrs — |
| 24 | JANE STREET GROUP, LLC | 14.9K +14.9K (+100.0%) | 9.4K +9.4K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD0.63 +0.0% | 8 qtrs — |
| 25 | CREATIVE PLANNING | 12.6K +2.4K (+23.0%) | 8.0K +80.0 (+1.0%) | 0.03% +0.005 pp | 0.00% +0.000 pp | USD0.74 -14.9% | 2 qtrs — |
| 26 | PINGORA PARTNERS LLC | 12.0K +— (+0.0%) | 7.6K -1.7K (-17.9%) | 0.02% 0.000 pp | 0.00% -0.002 pp | USD0.95 -33.7% | 4 qtrs — |
| 27 | US BANCORP \DE\ | 3.1K +— (+0.0%) | 2.0K -427.0 (-17.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD4.34 -85.5% | 22 qtrs — |
| 28 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2.5K +— (+0.0%) | 1.6K -342.0 (-17.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.22 -48.4% | 13 qtrs — |
| 29 | BANK OF AMERICA CORP /DE/ | 1.9K +14.0 (+0.7%) | 1.2K -250.0 (-17.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.92 -67.2% | 22 qtrs — |
| 30 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.8K -824.0 (-31.3%) | 1.1K -883.0 (-43.6%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD0.67 -6.0% | 22 qtrs — |
| 31 | ADVISOR GROUP HOLDINGS, INC. | 1.7K +— (+0.0%) | 1.1K -335.0 (-23.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.78 -77.3% | 22 qtrs — |
| 32 | CITIGROUP INC | 1.4K -4.9K (-78.0%) | 872.00 -4.0K (-82.0%) | 0.00% -0.010 pp | 0.00% +0.000 pp | USD0.77 -18.2% | 2 qtrs — |
| 33 | HIGHMARK WEALTH MANAGEMENT LLC | 1.1K +— (+0.0%) | 674.00 -147.0 (-17.9%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD6.15 -89.8% | 22 qtrs — |
| 34 | MAI CAPITAL MANAGEMENT | 500.00 +500.0 (+100.0%) | 317.00 +317.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.63 +0.0% | 1 qtrs NEW |
| 35 | SBI SECURITIES CO., LTD. | 232.00 -6.0 (-2.5%) | 147.00 -36.0 (-19.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.20 -47.5% | 5 qtrs — |
| 36 | SAGEVIEW ADVISORY GROUP, LLC | 39.00 +39.0 (+100.0%) | 25.00 +25.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.62 +1.6% | 1 qtrs NEW |
| 37 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | — -14.2K (-100.0%) | — -11.3K (-100.0%) | 0.00% -0.029 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 38 | WEALTHSPIRE ADVISORS, LLC | — -3.0K (-100.0%) | — -2.3K (-100.0%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 39 | WELLS FARGO & COMPANY/MN | — -6.8K (-100.0%) | — -5.2K (-100.0%) | 0.00% -0.014 pp | 0.00% +0.000 pp | USD— | 21 qtrs SOLD |
| 40 | CHICAGO PARTNERS INVESTMENT GROUP LLC | — -10.3K (-100.0%) | — -7.4K (-100.0%) | 0.00% -0.021 pp | 0.00% 0.000 pp | USD— | 17 qtrs SOLD |
| 41 | SEQUOIA FINANCIAL ADVISORS, LLC | — -52.9K (-100.0%) | — -40.7K (-100.0%) | 0.00% -0.106 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 42 | KINGDON CAPITAL MANAGEMENT, L.L.C. | — -2.2M (-100.0%) | — -1.7M (-100.0%) | 0.00% -4.497 pp | 0.00% -0.214 pp | USD— | 22 qtrs SOLD |
| 43 | FMR LLC | — -1.5K (-100.0%) | — -1.2K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 44 | FEDERATED HERMES, INC. | — -1.6M (-100.0%) | — -1.2M (-100.0%) | 0.00% -3.183 pp | 0.00% -0.002 pp | USD— | 22 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | EA Bridgeway Omni Small-Cap Value ETF BSVO | 0.00% | 50.2K | 0.47% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 337.5K | 0.05% |
| 3 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 22.5K | 0.43% |
| 4 | Dimensional - US Small Cap ETF DFAS | 0.00% | 23.7K | 0.26% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 346.76 | 0.17% |
| 6 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.7K | 0.03% |
| 7 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 4.7K | 0.17% |
| 8 | Vanguard Total Stock Market ETF VTI | 0.00% | 802.2K | 0.03% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.8K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 957.21 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
217.4K
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+217,390
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Angulo Gonzalez David | Director / Officer | P-Purchase | A | Common Stock | 108,695 | 0.00 | — | 1,357,126 | D | ↗ |
| 2026-01-29 | Sukenick Scott | Officer | A-Award | A | Common Stock | 129,833 | 0.00 | — | 574,539 | D | ↗ |
| 2026-01-29 | Macleod ivor | Officer | A-Award | A | Common Stock | 129,833 | 0.00 | — | 398,529 | D | ↗ |
| 2026-01-29 | Angulo Gonzalez David | Director / Officer | A-Award | A | Common Stock | 391,333 | 0.00 | — | 1,244,431 | D | ↗ |
| 2025-10-17 | Angulo Gonzalez David | Director / Officer | A-Award | A | Common Stock | 32,500 | 0.76 | 24.7K | 853,098 | D | ↗ |
| 2025-06-26 | Tinmouth Brian Philippe | Director | A-Award | A | Stock Option | 23,000 | 0.74 | 17.0K | 23,000 | D | ↗ |
| 2025-06-26 | Macdonald Guy | Director | A-Award | A | Common Stock | 23,000 | 0.00 | — | 78,000 | D | ↗ |
| 2025-06-26 | HASTINGS DAVID C | Director | A-Award | A | Stock Option | 23,000 | 0.74 | 17.0K | 23,000 | D | ↗ |
| 2025-06-26 | HANHAM ANN | Director | A-Award | A | Stock Option | 23,000 | 0.74 | 17.0K | 23,000 | D | ↗ |
| 2025-06-26 | GILMAN STEVEN C | Director | A-Award | A | Stock Option | 23,000 | 0.74 | 17.0K | 23,000 | D | ↗ |
| 2025-06-26 | ANIDO ARMANDO | Director | A-Award | A | Stock Option | 23,000 | 0.74 | 17.0K | 23,000 | D | ↗ |
| 2025-04-09 | Angulo Gonzalez David | Director / Officer | A-Award | A | Common Stock | 23,000 | 0.84 | 19.3K | 816,598 | D | ↗ |
| 2025-03-20 | Angulo Gonzalez David | Director / Officer | A-Award | A | Common Stock | 13,800 | 1.05 | 14.5K | 793,598 | D | ↗ |
| 2025-03-19 | Angulo Gonzalez David | Director / Officer | A-Award | A | Common Stock | 5,000 | 1.07 | 5.4K | 779,798 | D | ↗ |
| 2025-01-23 | Sukenick Scott | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 138,767 | 1.08 | 149.9K | 138,767 | D | ↗ |
| 2025-01-23 | Macleod ivor | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 138,767 | 1.08 | 149.9K | 138,767 | D | ↗ |
| 2025-01-23 | Angulo Gonzalez David | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 394,391 | 1.08 | 425.9K | 394,391 | D | ↗ |
| 2024-09-12 | Angulo Gonzalez David | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 1.37 | 27.4K | 507,871 | — | ↗ |
| 2024-06-20 | Tinmouth Brian Philippe | Director | A-Award | A | Common Stock | 23,000 | 0.00 | — | 51,000 | — | ↗ |
| 2024-06-20 | Macdonald Guy | Director | A-Award | A | Stock Option | 23,000 | 1.88 | 43.2K | 23,000 | — | ↗ |
| 2024-06-20 | HASTINGS DAVID C | Director | A-Award | A | Stock Option | 23,000 | 1.88 | 43.2K | 23,000 | — | ↗ |
| 2024-06-20 | HANHAM ANN | Director | A-Award | A | Stock Option | 23,000 | 1.88 | 43.2K | 23,000 | — | ↗ |
| 2024-06-20 | GILMAN STEVEN C | Director | A-Award | A | Stock Option | 23,000 | 1.88 | 43.2K | 23,000 | — | ↗ |
| 2024-06-20 | ANIDO ARMANDO | Director | A-Award | A | Stock Option | 23,000 | 1.88 | 43.2K | 23,000 | — | ↗ |
| 2024-02-16 | Sukenick Scott | Officer | F-InKind | D | Common Stock | 15,179 | 1.63 | 24.7K | 336,195 | — | ↗ |
| 2024-01-26 | Sukenick Scott | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 215,515 | 1.86 | 400.9K | 215,515 | — | ↗ |
| 2024-01-26 | Macleod ivor | Officer | A-Award | A | Common Stock | 143,675 | 0.00 | — | 160,185 | — | ↗ |
| 2024-01-26 | Angulo Gonzalez David | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 431,030 | 1.86 | 801.7K | 431,030 | — | ↗ |
| 2023-06-15 | Tinmouth Brian Philippe | Director | A-Award | A | Stock Option | 10,000 | 2.74 | 27.4K | 10,000 | — | ↗ |
| 2023-06-15 | Macdonald Guy | Director | A-Award | A | Stock Option | 10,000 | 2.74 | 27.4K | 10,000 | — | ↗ |
| 2023-06-15 | HASTINGS DAVID C | Director | A-Award | A | Stock Option | 10,000 | 2.74 | 27.4K | 10,000 | — | ↗ |
| 2023-06-15 | HANHAM ANN | Director | A-Award | A | Stock Option | 10,000 | 2.74 | 27.4K | 10,000 | — | ↗ |
| 2023-06-15 | GILMAN STEVEN C | Director | A-Award | A | Stock Option | 10,000 | 2.74 | 27.4K | 10,000 | — | ↗ |
| 2023-06-15 | ANIDO ARMANDO | Director | A-Award | A | Stock Option | 10,000 | 2.74 | 27.4K | 10,000 | — | ↗ |
| 2023-05-15 | Sukenick Scott | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 203,599 | — | ↗ |
| 2023-01-27 | Sukenick Scott | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 153,599 | — | ↗ |
| 2023-01-01 | Angulo Gonzalez David | Officer | A-Award | A | Common Stock | 110,000 | 0.00 | — | 185,181 | — | ↗ |
| 2022-10-24 | Macleod ivor | Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-17 | Tinmouth Brian Philippe | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-17 | Macdonald Guy | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-06-17 | HASTINGS DAVID C | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-17 | HANHAM ANN | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 13,622 | — | ↗ |
| 2022-06-17 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-17 | ANIDO ARMANDO | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-04-26 | Taglietti Marco | Officer | P-Purchase | A | Common Stock | 75,000 | 3.00 | 225.0K | 272,068 | — | ↗ |
| 2022-04-26 | Sukenick Scott | Officer | P-Purchase | A | Common Stock | 3,500 | 3.00 | 10.5K | 53,499 | — | ↗ |
| 2022-02-04 | Taglietti Marco | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 232,000 | 4.60 | 1.07M | 232,000 | — | ↗ |
| 2022-02-04 | Sukenick Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 4.60 | 322.0K | 70,000 | — | ↗ |
| 2022-02-04 | Coyne Christine | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 4.60 | 345.0K | 75,000 | — | ↗ |
| 2022-02-04 | Angulo Gonzalez David | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 4.60 | 391.0K | 85,000 | — | ↗ |
| 2021-11-22 | HOFFMAN LAWRENCE R | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-16 | Tinmouth Brian Philippe | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 7.51 | 75.1K | 10,000 | — | ↗ |
| 2021-06-16 | Macdonald Guy | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 7.51 | 75.1K | 10,000 | — | ↗ |
| 2021-06-16 | HASTINGS DAVID C | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 7.51 | 75.1K | 10,000 | — | ↗ |
| 2021-06-16 | HANHAM ANN | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 7.51 | 75.1K | 10,000 | — | ↗ |
| 2021-06-16 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 7.51 | 75.1K | 10,000 | — | ↗ |
| 2021-06-16 | ANIDO ARMANDO | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 7.51 | 75.1K | 10,000 | — | ↗ |
| 2021-05-10 | Coyne Christine | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 6.50 | 812.5K | 125,000 | — | ↗ |
| 2021-01-29 | Taglietti Marco | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 170,000 | 7.47 | 1.27M | 170,000 | — | ↗ |
| 2021-01-29 | Sukenick Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 7.47 | 298.8K | 40,000 | — | ↗ |
| 2021-01-29 | Francois Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 7.47 | 485.6K | 65,000 | — | ↗ |
| 2021-01-29 | Angulo Gonzalez David | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 7.47 | 485.6K | 65,000 | — | ↗ |
| 2021-01-22 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 33,849 | 8.95 | 302.9K | 1,800,000 | — | ↗ |
| 2021-01-21 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 95,000 | 7.38 | 701.1K | 2,120,000 | — | ↗ |
| 2021-01-20 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 185,000 | 7.43 | 1.37M | 2,215,000 | — | ↗ |
| 2020-12-21 | Tinmouth Brian Philippe | Director | A-Award | A | Common Stock Warrant | 4,000 | 8.25 | 33.0K | 4,000 | — | ↗ |
| 2020-12-21 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 40,000 | 6.25 | 250.0K | 109,668 | — | ↗ |
| 2020-12-21 | Sukenick Scott | Officer | A-Award | A | Common Stock Warrant | 800 | 8.25 | 6.6K | 800 | — | ↗ |
| 2020-12-21 | PERCEPTIVE ADVISORS LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,400,000 | — | ↗ |
| 2020-12-21 | Macdonald Guy | Director | A-Award | A | Common Stock Warrant | 4,000 | 7.33 | 29.3K | 4,000 | — | ↗ |
| 2020-12-21 | HANHAM ANN | Director | A-Award | A | Common Stock Warrant | 1,600 | 8.25 | 13.2K | 1,600 | — | ↗ |
| 2020-12-21 | GILMAN STEVEN C | Director | A-Award | A | Common Stock Warrant | 2,000 | 8.25 | 16.5K | 2,000 | — | ↗ |
| 2020-12-21 | Francois Eric | Officer | P-Purchase | A | Common Stock | 600 | 6.25 | 3.8K | 11,732 | — | ↗ |
| 2020-12-21 | Angulo Gonzalez David | Officer | P-Purchase | A | Common Stock | 1,600 | 6.25 | 10.0K | 23,780 | — | ↗ |
| 2020-12-21 | ANIDO ARMANDO | Director | P-Purchase | A | Common Stock | 5,000 | 6.25 | 31.3K | 5,000 | — | ↗ |
| 2020-11-25 | Sukenick Scott | Officer | F-InKind | D | Common Stock | 2,613 | 6.81 | 17.8K | 7,499 | — | ↗ |
| 2020-11-25 | Francois Eric | Officer | F-InKind | D | Common Stock | 3,480 | 6.81 | 23.7K | 11,132 | — | ↗ |
| 2020-11-25 | Angulo Gonzalez David | Officer | F-InKind | D | Common Stock | 4,323 | 6.81 | 29.4K | 22,180 | — | ↗ |
| 2020-07-06 | Tinmouth Brian Philippe | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 0.73 | 32.9K | 45,000 | — | ↗ |
| 2020-07-06 | Macdonald Guy | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2020-07-06 | HASTINGS DAVID C | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 0.73 | 32.9K | 45,000 | — | ↗ |
| 2020-07-06 | HANHAM ANN | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 0.73 | 32.9K | 45,000 | — | ↗ |
| 2020-07-06 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 0.73 | 32.9K | 45,000 | — | ↗ |
| 2020-07-06 | ANIDO ARMANDO | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 0.73 | 32.9K | 45,000 | — | ↗ |
| 2020-02-15 | Sukenick Scott | Officer | F-InKind | D | Common Stock | 783 | 9.80 | 7.7K | 9,912 | — | ↗ |
| 2020-02-15 | Francois Eric | Officer | F-InKind | D | Common Stock | 979 | 9.80 | 9.6K | 14,412 | — | ↗ |
| 2020-02-15 | Angulo Gonzalez David | Officer | F-InKind | D | Common Stock | 1,175 | 9.80 | 11.5K | 26,303 | — | ↗ |
| 2020-01-31 | Taglietti Marco | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 900,000 | 0.86 | 776.7K | 900,000 | — | ↗ |
| 2020-01-31 | Sukenick Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.86 | 215.8K | 250,000 | — | ↗ |
| 2020-01-31 | Francois Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 0.86 | 323.6K | 375,000 | — | ↗ |
| 2020-01-31 | Angulo Gonzalez David | Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 0.86 | 388.4K | 450,000 | — | ↗ |
| 2019-12-13 | Tinmouth Brian Philippe | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 0.73 | 51.1K | 70,000 | — | ↗ |
| 2019-12-12 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock Warrant (right to buy) | 166,667 | 1.10 | 183.3K | 166,667 | — | ↗ |
| 2019-08-21 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 9,500 | 1.11 | 10.5K | 526,015 | — | ↗ |
| 2019-08-20 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 500 | 1.11 | 555.00 | 516,515 | — | ↗ |
| 2019-08-15 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 10,015 | 1.01 | 10.1K | 516,015 | — | ↗ |
| 2019-06-18 | Macdonald Guy | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 1.29 | 58.1K | 45,000 | — | ↗ |
| 2019-06-18 | HASTINGS DAVID C | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 1.29 | 58.1K | 45,000 | — | ↗ |
| 2019-06-18 | HANHAM ANN | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 1.29 | 58.1K | 45,000 | — | ↗ |
| 2019-06-18 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 1.29 | 58.1K | 45,000 | — | ↗ |
| 2019-06-18 | ANIDO ARMANDO | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 1.29 | 58.1K | 45,000 | — | ↗ |
| 2019-04-17 | Taglietti Marco | Officer | P-Purchase | A | Common Stock | 25,000 | 1.63 | 40.8K | 506,000 | — | ↗ |
| 2019-02-15 | Taglietti Marco | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 1.38 | 966.0K | 700,000 | — | ↗ |
| 2019-02-15 | Sukenick Scott | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 102,959 | — | ↗ |
| 2019-02-15 | Francois Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 1.38 | 172.5K | 125,000 | — | ↗ |
| 2019-02-15 | Angulo Gonzalez David | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 1.38 | 207.0K | 150,000 | — | ↗ |
| 2019-01-21 | ANIDO ARMANDO | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-01-10 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 0.69 | 17.3K | 480,000 | — | ↗ |
| 2019-01-02 | Machado Patrick | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.54 | 12.2K | 22,500 | — | ↗ |
| 2019-01-02 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.54 | 12.2K | 22,500 | — | ↗ |
| 2019-01-02 | HASTINGS DAVID C | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.54 | 12.2K | 22,500 | — | ↗ |
| 2019-01-02 | HANHAM ANN | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.54 | 12.2K | 22,500 | — | ↗ |
| 2019-01-02 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.54 | 12.2K | 22,500 | — | ↗ |
| 2018-12-31 | Taglietti Marco | Director / Officer | P-Purchase | A | Common stock | 25,000 | 0.46 | 11.5K | 455,000 | — | ↗ |
| 2018-12-31 | Angulo Gonzalez David | Officer | P-Purchase | A | Common stock | 12,000 | 0.50 | 6.0K | 121,790 | — | ↗ |
| 2018-10-01 | Macdonald Guy | Director | A-Award | A | Stock option (right to buy) | 21,595 | 1.22 | 26.3K | 21,595 | — | ↗ |
| 2018-09-06 | Angulo Gonzalez David | Officer | P-Purchase | A | Common Stock | 7,000 | 1.27 | 8.9K | 108,790 | — | ↗ |
| 2018-08-23 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 1.29 | 32.3K | 429,000 | — | ↗ |
| 2018-07-02 | McCourt Marion | Director | A-Award | A | Stock option (right to buy) | 9,217 | 1.10 | 10.1K | 9,217 | — | ↗ |
| 2018-07-02 | Macdonald Guy | Director | A-Award | A | Stock option (right to buy) | 15,589 | 1.69 | 26.3K | 15,589 | — | ↗ |
| 2018-04-02 | McCourt Marion | Director | A-Award | A | Stock option (right to buy) | 11,800 | 1.32 | 15.6K | 11,800 | — | ↗ |
| 2018-04-02 | Macdonald Guy | Director | A-Award | A | Stock option (right to buy) | 19,959 | 1.32 | 26.3K | 19,959 | — | ↗ |
| 2018-03-29 | Angulo Gonzalez David | Officer | P-Purchase | A | Common Stock | 6,000 | 1.36 | 8.2K | 101,790 | — | ↗ |
| 2018-03-08 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock Warrant (right to buy) | 75,000 | 1.85 | 138.8K | 75,000 | — | ↗ |
| 2018-03-08 | Sukenick Scott | Officer | P-Purchase | A | Common Stock Warrant (right to buy) | 1,331 | 2.00 | 2.7K | 1,331 | — | ↗ |
| 2018-03-08 | HASTINGS DAVID C | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 8,875 | 1.85 | 16.4K | 8,875 | — | ↗ |
| 2018-03-08 | Francois Eric | Officer | P-Purchase | A | Common Stock Warrant (right to buy) | 4,437 | 1.85 | 8.2K | 4,437 | — | ↗ |
| 2018-03-08 | Angulo Gonzalez David | Officer | P-Purchase | A | Common Stock Warrant (right to buy) | 6,655 | 2.00 | 13.3K | 6,655 | — | ↗ |
| 2018-02-09 | Taglietti Marco | Director / Officer | A-Award | A | Stock option (right to buy) | 375,000 | 1.69 | 633.8K | 375,000 | — | ↗ |
| 2018-02-09 | Sukenick Scott | Officer | A-Award | A | Stock option (right to buy) | 15,000 | 1.69 | 25.4K | 15,000 | — | ↗ |
| 2018-02-09 | Francois Eric | Officer | A-Award | A | Stock option (right to buy) | 150,000 | 1.69 | 253.5K | 150,000 | — | ↗ |
| 2018-02-09 | Angulo Gonzalez David | Officer | A-Award | A | Stock option (right to buy) | 200,000 | 1.69 | 338.0K | 200,000 | — | ↗ |
| 2018-01-02 | McCourt Marion | Director | A-Award | A | Stock Option (right to buy) | 19,989 | 2.28 | 45.6K | 19,989 | — | ↗ |
| 2018-01-02 | Machado Patrick | Director | A-Award | A | Stock Option (right to buy) | 19,989 | 2.28 | 45.6K | 19,989 | — | ↗ |
| 2018-01-02 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 19,989 | 2.28 | 45.6K | 19,989 | — | ↗ |
| 2018-01-02 | HASTINGS DAVID C | Director | A-Award | A | Stock Option (right to buy) | 19,989 | 2.28 | 45.6K | 19,989 | — | ↗ |
| 2018-01-02 | HANHAM ANN | Director | A-Award | A | Stock Option (right to buy) | 19,989 | 2.28 | 45.6K | 19,989 | — | ↗ |
| 2018-01-02 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 19,989 | 2.28 | 45.6K | 19,989 | — | ↗ |
| 2017-11-15 | Sukenick Scott | Officer | A-Award | A | Stock Option (right to buy) | 160,000 | 1.75 | 280.0K | 160,000 | — | ↗ |
| 2017-10-02 | McCourt Marion | Director | A-Award | A | Stock Option (right to buy) | 6,332 | 2.46 | 15.6K | 6,332 | — | ↗ |
| 2017-10-02 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 10,709 | 2.46 | 26.3K | 10,709 | — | ↗ |
| 2017-10-02 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 1,807 | 2.46 | 4.4K | 1,807 | — | ↗ |
| 2017-09-22 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 2.23 | 22.3K | 303,000 | — | ↗ |
| 2017-08-23 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 4,993 | 1.85 | 9.2K | 292,000 | — | ↗ |
| 2017-08-22 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 7 | 1.61 | 11.27 | 287,007 | — | ↗ |
| 2017-08-15 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.61 | 16.1K | 287,000 | — | ↗ |
| 2017-08-11 | Angulo Gonzalez David | Officer | P-Purchase | A | Common Stock | 10,000 | 1.55 | 15.5K | 72,000 | — | ↗ |
| 2017-07-03 | McCourt Marion | Director | A-Award | A | Stock Option (right to buy) | 8,511 | 1.83 | 15.6K | 8,511 | — | ↗ |
| 2017-07-03 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 14,396 | 1.83 | 26.3K | 14,396 | — | ↗ |
| 2017-07-03 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 2,430 | 1.83 | 4.4K | 2,430 | — | ↗ |
| 2017-06-21 | HASTINGS DAVID C | Director | P-Purchase | A | Common Stock | 20,000 | 1.75 | 35.0K | 20,000 | — | ↗ |
| 2017-05-12 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 1.69 | 42.3K | 277,000 | — | ↗ |
| 2017-05-12 | Angulo Gonzalez David | Officer | P-Purchase | A | Common Stock | 15,000 | 1.70 | 25.5K | 62,000 | — | ↗ |
| 2017-04-03 | McCourt Marion | Director | A-Award | A | Stock Option (right to buy) | 5,878 | 2.65 | 15.6K | 5,878 | — | ↗ |
| 2017-04-03 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 9,941 | 2.65 | 26.3K | 9,941 | — | ↗ |
| 2017-04-03 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 1,678 | 2.65 | 4.4K | 1,678 | — | ↗ |
| 2017-01-31 | Taglietti Marco | Director / Officer | A-Award | A | Stock Option (right to buy) | 360,000 | 3.02 | 1.09M | 360,000 | — | ↗ |
| 2017-01-31 | Francois Eric | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 3.02 | 302.0K | 100,000 | — | ↗ |
| 2017-01-31 | Angulo Gonzalez David | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 3.02 | 422.8K | 140,000 | — | ↗ |
| 2017-01-25 | McCourt Marion | Director | A-Award | A | Stock Option (right to buy) | 4,274 | 3.15 | 13.5K | 4,274 | — | ↗ |
| 2017-01-03 | Machado Patrick | Director | A-Award | A | Stock Option (right to buy) | 14,499 | 3.40 | 49.3K | 14,499 | — | ↗ |
| 2017-01-03 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 14,499 | 3.40 | 49.3K | 14,499 | — | ↗ |
| 2017-01-03 | Langlois Patrick | Director | A-Award | A | Stock Option (right to buy) | 14,499 | 3.40 | 49.3K | 14,499 | — | ↗ |
| 2017-01-03 | HASTINGS DAVID C | Director | A-Award | A | Stock Option (right to buy) | 14,499 | 0.00 | — | 14,499 | — | ↗ |
| 2017-01-03 | HANHAM ANN | Director | A-Award | A | Stock Option (right to buy) | 14,499 | 3.40 | 49.3K | 14,499 | — | ↗ |
| 2017-01-03 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 1,308 | 3.40 | 4.4K | 1,308 | — | ↗ |
| 2016-12-21 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 3.30 | 82.5K | 251,000 | — | ↗ |
| 2016-12-16 | Angulo Gonzalez David | Officer | P-Purchase | A | Common Stock | 4,000 | 3.25 | 13.0K | 46,000 | — | ↗ |
| 2016-10-03 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 6,255 | 4.55 | 28.5K | 6,255 | — | ↗ |
| 2016-10-03 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 977 | 4.55 | 4.4K | 977 | — | ↗ |
| 2016-09-15 | Machado Patrick | Director | P-Purchase | A | Common Stock | 40,000 | 2.94 | 117.6K | 60,000 | — | ↗ |
| 2016-07-01 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 12,996 | 2.19 | 28.5K | 12,996 | — | ↗ |
| 2016-07-01 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 2,030 | 2.19 | 4.4K | 2,030 | — | ↗ |
| 2016-06-30 | Angulo Gonzalez David | Officer | P-Purchase | A | Common Stock | 32,150 | 2.23 | 71.7K | 41,000 | — | ↗ |
| 2016-06-29 | Angulo Gonzalez David | Officer | P-Purchase | A | Common Stock | 4,800 | 2.18 | 10.5K | 8,850 | — | ↗ |
| 2016-06-24 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock Warrant (right to buy) | 45,000 | 3.00 | 135.0K | 45,000 | — | ↗ |
| 2016-06-24 | Machado Clarence Patrick | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 9,000 | 0.02 | 180.00 | 9,000 | — | ↗ |
| 2016-06-24 | Macdonald Guy | Director | P-Purchase | A | Common Stock | 40,000 | 2.39 | 95.6K | 40,000 | — | ↗ |
| 2016-06-24 | Francois Eric | Officer | P-Purchase | A | Common Stock Warrant (right to buy) | 6,750 | 3.00 | 20.3K | 6,750 | — | ↗ |
| 2016-06-02 | Machado Clarence Patrick | Director | A-Award | A | Stock Option (right to buy) | 8,800 | 3.98 | 35.0K | 8,800 | — | ↗ |
| 2016-06-02 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 8,800 | 3.98 | 35.0K | 8,800 | — | ↗ |
| 2016-06-02 | Langlois Patrick | Director | A-Award | A | Stock Option (right to buy) | 8,800 | 3.98 | 35.0K | 8,800 | — | ↗ |
| 2016-06-02 | HASTINGS DAVID C | Director | A-Award | A | Stock Option (right to buy) | 8,800 | 3.98 | 35.0K | 8,800 | — | ↗ |
| 2016-06-02 | HANHAM ANN | Director | A-Award | A | Stock Option (right to buy) | 8,800 | 3.98 | 35.0K | 8,800 | — | ↗ |
| 2016-06-02 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 8,800 | 3.98 | 35.0K | 8,800 | — | ↗ |
| 2016-05-25 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 246 | 3.20 | 787.20 | 125,000 | — | ↗ |
| 2016-05-25 | HANHAM ANN | Director | P-Purchase | A | Common Stock | 4,225 | 3.64 | 15.4K | 4,225 | — | ↗ |
| 2016-05-24 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 5,500 | 3.37 | 18.5K | 119,000 | — | ↗ |
| 2016-05-23 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 3.15 | 9.5K | 113,500 | — | ↗ |
| 2016-05-20 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 4,500 | 3.14 | 14.1K | 110,500 | — | ↗ |
| 2016-05-19 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 6,000 | 3.07 | 18.4K | 106,000 | — | ↗ |
| 2016-04-01 | Taglietti Marco | Director / Officer | A-Award | A | Stock Option (right to buy) | 185,000 | 4.05 | 749.3K | 185,000 | — | ↗ |
| 2016-04-01 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 7,027 | 4.05 | 28.5K | 7,027 | — | ↗ |
| 2016-04-01 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 1,098 | 4.05 | 4.4K | 1,098 | — | ↗ |
| 2016-04-01 | Francois Eric | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 4.05 | 81.0K | 20,000 | — | ↗ |
| 2016-04-01 | Angulo Gonzalez David | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 4.05 | 283.5K | 70,000 | — | ↗ |
| 2016-01-04 | Macdonald Guy | Director | A-Award | A | Stock Option (right to buy) | 4,666 | 6.10 | 28.5K | 4,666 | — | ↗ |
| 2016-01-04 | GILMAN STEVEN C | Director | A-Award | A | Stock Option (right to buy) | 729 | 6.10 | 4.4K | 729 | — | ↗ |
| 2015-11-24 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 7,733 | 6.80 | 52.6K | 100,000 | — | ↗ |
| 2015-11-23 | Taglietti Marco | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 6.79 | 101.9K | 92,267 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-468.7K
Shares Outstanding
50.36M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | David Angulo, M.D. President and Chief Executive Officer | 626.0K | — | 284.0K | 307.3K | 312.4K | 10.5K | 1.54M | 38.39% | ↗ |
| 2 | 2025 | Ivor Macleod Chief Financial Officer | 467.5K | — | 99.9K | 108.1K | 173.1K | 10.5K | 859.2K | 24.21% | ↗ |
| 3 | 2025 | Scott Sukenick Chief Legal Officer | 460.0K | — | 99.9K | 108.1K | 172.2K | 10.5K | 833.0K | 24.97% | ↗ |
| 4 | 2024 | David Angulo, M.D. President and Chief Executive Officer | 595.3K | — | 540.5K | 574.3K | 307.4K | 10.4K | 2.03M | 54.97% | ↗ |
| 5 | 2024 | Ivor Macleod Chief Financial Officer | 449.5K | — | 267.2K | 287.1K | 171.9K | 10.4K | 1.19M | 46.74% | ↗ |
| 6 | 2024 | Scott Sukenick Chief Legal Officer | 442.3K | — | 267.2K | 287.1K | 169.1K | 10.4K | 1.18M | 47.13% | ↗ |
| 7 | 2023 | David Angulo, M.D. President and Chief Executive Officer | 565.0K | — | 171.6K | 175.1K | 265.0K | 38.0K | 1.21M | 28.54% | ↗ |
| 8 | 2023 | Scott Sukenick Chief Legal Officer | 423.3K | — | 313.0K | — | 153.1K | 47.3K | 936.7K | 33.42% | ↗ |
| 9 | 2023 | Ivor Macleod Chief Financial Officer | 435.0K | — | — | — | 155.6K | 36.3K | 626.9K | 0.00% | ↗ |
| 10 | 2022 | Marco Taglietti, M.D. Former President and Chief Executive Officer | 598.6K | — | 479.6K | 699.0K | 186.0K | 645.6K | 2.61M | 45.18% | ↗ |
| 11 | 2022 | David Angulo, M.D. President and Chief Executive Officer | 482.3K | — | 281.1K | 256.1K | 125.7K | 23.7K | 1.17M | 45.96% | ↗ |
| 12 | 2022 | Christine Coyne Former Chief Commercial Officer | 369.7K | — | 237.6K | 226.0K | 83.0K | 247.9K | 1.16M | 39.82% | ↗ |
| 13 | 2022 | Scott Sukenick Chief Legal Officer | 395.3K | — | 223.9K | 210.9K | 103.7K | 43.1K | 976.8K | 44.51% | ↗ |
| 14 | 2022 | Scott Sukenick General Counsel | 395.3K | — | 223.9K | 210.9K | 103.7K | 43.1K | 976.8K | 44.51% | ↗ |
| 15 | 2021 | Marco Taglietti, M.D. President and Chief Executive Officer | 569.5K | — | — | 808.3K | 287.0K | 49.4K | 1.71M | 47.15% | ↗ |
| 16 | 2021 | Marco Taglietti, M.D. Former President and Chief Executive Officer | 569.5K | — | — | 808.3K | 287.0K | 49.4K | 1.71M | 47.15% | ↗ |
| 17 | 2021 | Christine Coyne Former Chief Commercial Officer | 254.5K | — | 97.5K | 521.1K | 135.0K | 25.1K | 1.03M | 59.87% | ↗ |
| 18 | 2021 | Christine Coyne Chief Commercial Officer | 254.5K | — | 97.5K | 521.1K | 135.0K | 25.1K | 1.03M | 59.87% | ↗ |
| 19 | 2021 | David Angulo, M.D. Chief Medical Officer | 461.2K | — | — | 309.1K | 179.9K | 37.3K | 987.5K | 31.30% | ↗ |
| 20 | 2021 | David Angulo, M.D. President and Chief Executive Officer | 461.2K | — | — | 309.1K | 179.9K | 37.3K | 987.5K | 31.30% | ↗ |
| 21 | 2020 | Marco Taglietti, M.D. President and Chief Executive Officer | 553.0K | — | — | 458.3K | 386.0K | 52.3K | 1.45M | 31.62% | ↗ |
| 22 | 2020 | David Angulo, M.D. Chief Medical Officer | 447.3K | — | — | 229.1K | 227.5K | 34.9K | 938.8K | 24.41% | ↗ |
| 23 | 2020 | Eric Francois Chief Financial Officer | 391.3K | — | — | 190.9K | 198.2K | 44.7K | 825.2K | 23.14% | ↗ |
| 24 | 2019 | Marco Taglietti, M.D. President and Chief Executive Officer | 542.5K | — | — | 597.2K | 344.7K | 50.1K | 1.53M | 38.92% | ↗ |
| 25 | 2019 | David Angulo, M.D. Chief Medical Officer | 437.0K | — | 207.0K | 128.0K | 202.0K | 37.2K | 1.01M | 33.13% | ↗ |
| 26 | 2019 | Eric Francois Chief Financial Officer | 380.7K | — | 172.5K | 106.7K | 176.0K | 48.2K | 884.1K | 31.58% | ↗ |
| 27 | 2018 | Marco Taglietti, M.D. President and Chief Executive Officer | 526.7K | 219.0K | — | 324.5K | — | 44.8K | 1.11M | 29.10% | ↗ |
| 28 | 2018 | Marco Taglietti, M.D. President and Chief Executive Officer | 526.7K | — | — | 324.5K | 219.0K | 44.8K | 1.11M | 29.10% | ↗ |
| 29 | 2018 | David Angulo, M.D. Chief Medical Officer | 424.2K | 150.0K | — | 173.0K | — | 21.4K | 768.6K | 22.51% | ↗ |
| 30 | 2018 | David Angulo, M.D. Chief Medical Officer | 424.2K | — | — | 173.0K | 150.0K | 21.4K | 768.6K | 22.51% | ↗ |
| 31 | 2018 | Eric Francois Chief Financial Officer | 369.6K | — | — | 129.8K | 125.0K | 40.3K | 664.7K | 19.52% | ↗ |
| 32 | 2018 | Eric Francois Chief Financial Officer | 369.6K | 125.0K | — | 129.8K | — | 40.3K | 664.7K | 19.52% | ↗ |
| 33 | 2017 | Marco Taglietti, M.D. President and Chief Executive Officer | 507.4K | 140.3K | — | 549.0K | — | 24.0K | 1.22M | 44.97% | ↗ |
| 34 | 2017 | David Angulo, M.D. Chief Medical Officer | 411.8K | 124.2K | — | 213.5K | — | 18.1K | 767.5K | 27.81% | ↗ |
| 35 | 2017 | Eric Francois Chief Financial Officer | 358.8K | 97.4K | — | 152.5K | — | 37.0K | 645.7K | 23.62% | ↗ |
| 36 | 2016 | Marco Taglietti, M.D. President and Chief Executive Officer | 490.8K | 210.1K | — | 460.6K | — | 18.7K | 1.18M | 39.03% | ↗ |
| 37 | 2016 | David Angulo, M.D. Chief Medical Officer | 398.8K | 136.6K | — | 174.3K | — | 96.0K | 805.6K | 21.63% | ↗ |
| 38 | 2016 | Eric Francois Chief Financial Officer | 350.0K | 113.0K | — | 49.8K | — | 36.0K | 548.7K | 9.07% | ↗ |
| 39 | 2015 | Yves J. Ribeill, Ph.D. Director, Former CEO | 222.8K | 100.0K | — | 1.31M | — | 982.5K | 2.61M | 50.05% | ↗ |
| 40 | 2015 | Marco Taglietti, M.D. President and Chief Executive Officer | 360.0K | 264.0K | — | 1.69M | — | 3.7K | 2.32M | 72.92% | ↗ |
| 41 | 2015 | Marco Taglietti, M.D. President and Chief Executive Officer | 360.0K | 264.0K | — | 1.69M | — | 3.7K | 2.32M | 72.92% | ↗ |
| 42 | 2015 | David Angulo, M.D. Chief Medical Officer | 227.5K | 117.0K | — | 638.2K | — | 67.9K | 1.05M | 60.75% | ↗ |
| 43 | 2015 | David Angulo, M.D. Chief Medical Officer | 227.5K | 117.0K | — | 638.2K | — | 67.9K | 1.05M | 60.75% | ↗ |
| 44 | 2015 | Charles F. Osborne, Jr. Former Chief Financial Officer | 148.8K | 55.0K | — | 286.9K | — | 360.7K | 851.4K | 33.70% | ↗ |
| 45 | 2015 | Eric Francois Chief Financial Officer | 58.3K | 20.3K | — | 405.6K | — | 3.5K | 487.7K | 83.17% | ↗ |
| 46 | 2015 | Eric Francois Chief Financial Officer | 58.3K | 20.3K | — | 405.6K | — | 3.5K | 487.7K | 83.17% | ↗ |
| 47 | 2014 | Carole Sable Chief Medical Officer | 336.8K | 86.5K | — | 1.58M | — | 4.5K | 2.01M | 78.69% | ↗ |
| 48 | 2014 | Yves J. Ribeill, Ph.D. President and Chief Executive Officer | 337.6K | 195.6K | — | 798.4K | — | 9.7K | 1.34M | 59.53% | ↗ |
| 49 | 2014 | Yves J. Ribeill, Ph.D. Director, Former CEO | 337.6K | 195.6K | — | 798.4K | — | 9.7K | 1.34M | 59.53% | ↗ |
| 50 | 2014 | Charles F. Osborne, Jr. Former Chief Financial Officer | 272.1K | 60.0K | — | 237.8K | — | 9.2K | 579.1K | 41.06% | ↗ |
| 51 | 2014 | Charles F. Osborne, Jr. Chief Financial Officer | 272.1K | 60.0K | — | 237.8K | — | 9.2K | 579.1K | 41.06% | ↗ |
| 52 | 2013 | Yves J. Ribeill, Ph.D. President and Chief Executive Officer | 250.1K | — | — | — | — | 11.9K | 262.1K | 0.00% | ↗ |
| 53 | 2013 | Charles F. Osborne, Jr. Chief Financial Officer | 250.2K | — | — | — | — | 9.0K | 259.2K | 0.00% | ↗ |
| 54 | 2013 | Eileen C. Pruette General Counsel | 235.1K | — | — | — | — | 8.5K | 243.5K | 0.00% | ↗ |
| 55 | 2013 | Carole Sable Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 56 | 2012 | Yves J. Ribeill, Ph.D. President and Chief Executive Officer | 250.2K | — | — | — | — | 10.1K | 260.3K | 0.00% | ↗ |
| 57 | 2012 | Charles F. Osborne, Jr. Chief Financial Officer | 250.2K | — | — | — | — | 8.8K | 259.0K | 0.00% | ↗ |
| 58 | 2012 | Eileen C. Pruette General Counsel | 87.4K | — | — | 142.0K | — | 2.7K | 232.1K | 61.19% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Gonzalez Angulo | Chief Executive Officer, President & Director | 948.9K | male |
| Ivor Macleod | Chief Financial Officer | 651.1K | male |
| Scott Sukenick | Chief Legal Officer & Corporate Secretary | 642.7K | male |
| Daniella Gigante | Vice President of Human Resources & Information Technology | — | female |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SCYX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
